Patrick Walsh, "Treatment of Benign Prostatic Hyperplasia", New England Journal of Medicine, 335 (8):586-587, Aug. 22, 1996. |
Herbert Lepor et al., "The Efficacy of Terazosin, Finasteride, or Both in Benigh Prostatic Hyperplasia", New England Journal of Medicine, 335(8):533-539, Aug. 22, 1996. |
Jonathan M. Vapnek et al., "Combination Medical Therapy for Symptomatic Benign Prostatic Hyperplasia", Abstracts Western Section AUA 72nd Annual Meeting, Jul. 28-Aug. 1, 1996. |
Kumamoto et al., Clinical Efficacy of Oxendolene (Antiandrogen) and Bunazosin Hydrochloride (Alplha-Adrenergic Blocker) in the Treatment of Prostatism, 33 Hinyokika Kiyo 1921-1942 (1987). |
Hedlund et al., Effects of Prazosin in Patients with BPH, 130 J. Urol., pp. 275-278 (1983). |
Nagatomo et al., Adrenergic and Serotonergic Receptor-Blocking Potencies of Terazosin, a New Antihypertensive Agent, as Assessed by Radioligand Binding Assay, 35(4) Chem. Pharm. Bull. 1629-1632 (1987). |
The Finasteride Study Group, Finasteride (MK-906) in the Treatment of Benign Prostatic Hyperplasia, 22 Prostate 291-299 (1993). |
Caine et al., The Effect of Nicergoline on the Lower Urinary Tract Muscle, Chem. Abstr., CA102(11):90035s (1993). |
Caine et al., The Use of Alpha-Adrenergic Blockers in Benign Prostatic Obstruction, 48 Br. J. Urol. 255-263 (1976). |
Neri et al., Effects of a Novel Nonsteroidal Antiandrogen on Canine Prostatic Hyperplasia 10 Invest. Urol. 123-130 (1972). |
Nieschlag & Loriaux, Radioimmunoassay for Plasma Testosterone, 10 Z. klin. Chem. u. klin. Biochem. 164-168 (1972). |
Mandal & Vaidyanathan, Non-Operative Management of Symptomatic Benign Prostatic Hyperplasia, 6(2) Indian J. of Urol. 45-50 (1990). |
The Daily (Tuesday, May 7, 1996), "New Data on Proscar, Abbott's Hytrin Show Conflicting Results". |
Wall Street Journal (Tuesday, May 7, 1996), "Study Finds Abbott's Prostate Drug is Much More Effective than Merck's", p. B4. |
US News & World Report, May 20, 1996, "Zapping a problem prostate". |